Paul Rubinstein, MD
Medical Oncology · Chicago, ILNPI 1356518534
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,045 of the $8,461 with a category attached, or 71.4%. Seagen Inc. accounts for 92.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $3,674 and has fallen 99.4% since, to $23 in 2025.
Across 36 payments — averaging $235.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$8K
- Exelixis Inc.$190
- Pfizer$138
- Incyte Corporation$136
- Takeda Pharmaceuticals U.S.A., Inc.$47
- Bristol Myers Squibb$39
- plus $108 from 5 others
Across 20 payments — averaging $17,538 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$133K
- Genentech, Inc.$96K
- AbbVie$53K
- Seagen Inc.$40K
- National Marrow Donor Program$30K
What the payments were for
- Consulting fees$6,04571%
- Travel & lodging$3164%
- Food & beverage$2,07024%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 21 | $7,802 |
| Exelixis Inc. | 2 | $190 |
| Pfizer | 1 | $138 |
| Incyte Corporation | 3 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Bristol Myers Squibb | 2 | $39 |
| Amgen | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Merck | 1 | $21 |
| Novartis | 1 | $19 |
| Epizyme, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,461 in reported general payments places this provider in the 75th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 24 | $365,779 |
| JakafiRuxolitinib Phosphate | 12 | $182,567 |
| Imatinib Mesylate | 24 | $88,227 |
| Acyclovir | 15 | $371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $136 | $182,56712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 144 medical oncology providers in Illinois.
Other medical oncology in Chicago
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
- Jyoti PatelChicago$175K
- Al BensonChicago$163K
- Nisha MohindraChicago$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.